Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biktarvy for suspected acute HIV infection in the ED
NCT03711253Phase 4Unknown
- Sponsor
- University of Southern California
- Start
- Oct 2019
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of bictegravir + emtricitabine + tenofovir alafenamide in human immunodeficiency virus infection (HIV), sponsored by University of Southern California. Status: unknown.
02
Drugs
bictegravir + emtricitabine + tenofovir alafenamide
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03711253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03711253.